This is a demo store. No orders will be fulfilled.

PF-04802367 - 98%, high purity , CAS No.1962178-27-3

    Grade & Purity:
  • ≥98%
In stock
Item Number
P646646
Grouped product items
SKU Size
Availability
Price Qty
P646646-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$260.90
P646646-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$420.90
P646646-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$840.90
P646646-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,340.90

Basic Description

Specifications & Purity ≥98%
Biochemical and Physiological Mechanisms PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC 50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay.xa0PF-04802367 shows desirable central nervous system (CNS)xa0properties and potency. PF-
Storage Temp Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description

PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC 50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms ( GSK-3α and GSK-3β ) with IC 50 values of 10.0 and 9.0 nM in mobility shift assays, respectively

In Vitro

PF-04802367 (PF-367) is efficient at inhibiting GSK-3β enzymatic activity in vitro with ligand and lipophilic efficiency scores of 0.46 and 7.0, respectively. PF-367 has reasonable in vitro stability in human hepatic microsomes (t 1/2 =78.7 min), has excellent passive permeability. In a stable inducible CHO cell line over-expressing GSK-3β and its substrate tau, PF-367 inhibited phosphorylation of tau with an IC 50 of 466 nM. PF-367 has good cell viability (IC 50 of 117 μM in THLE cytotoxicity assays) and an IC 50 >100 μM in a hERG screening assay. PF-367 shows significant right shifts against β-catenin translocation in HeLa cells with EC 50 of 6.2 μM, gene transcription in U20S cells with EC 50 of 20.6 μM, and cell proliferation in HeLa cells as evaluated by Ki-67 incorporation with EC 50 of 9.0 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PF-04802367 (PF-367) a potent GSK-3 inhibitor with exceptional kinome selectivity that modulates phosphorylated tau levels in vivo. Inhibition of phosphorylation of tau in brain by PF-367 (A single subcutaneous of 1, 3.2, 10, 32 or 50 mg/kg) is dose-dependent . PF-04802367 (PF-367), a potent type-I dual GSK-3α/β inhibitor, showing promising absorption; distribution, metabolism and elimination (ADME) properties combined with robust CNS/peripheral p-Tau and muscle phosphorylated glycogen synthase (pGS) inhibition in vivo. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Sprague-Dawley rats Dosage: 1, 3.2, 10, 32 or 50 mg/kg Administration: A single subcutaneous Result: Inhibition of phosphorylation of tau in brain is dose-dependent.

Form:Solid

IC50& Target:GSK-3α 10 nM (IC 50 ) GSK-3β 9 nM (IC 50 )

Names and Identifiers

Smiles O=C(C1=C(C2=CC=C(OC)C(Cl)=C2)OC=N1)NCCCN3N=CN=C3
Molecular Weight 361.78

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Chemical and Physical Properties

Solubility DMSO : 100 mg/mL (276.41 mM; Need ultrasonic)

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.